Información de Organon & Co, dividendo de Organon & Co, actividades de los accionistas y más

Más Datos de Organon & Co Compañía

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Información de Organon & Co



Símbolo de cotizaciónOGN

Nombre de la empresaOrganon & Co

Fecha de salida a bolsaMay 14, 2021

Director ejecutivoMr. Kevin Ali

Número de empleados10000

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 14

Dirección30 Hudson Street

CiudadJERSEY CITY

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal07302

Teléfono15514306000

Sitio Webhttps://www.organon.com/

Símbolo de cotizaciónOGN

Fecha de salida a bolsaMay 14, 2021

Director ejecutivoMr. Kevin Ali

Ejecutivos de Organon & Co



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

144.48K

+8.57%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

71.89K

+18.29%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

59.92K

+10.11%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

52.85K

+17.96%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

41.33K

+26.65%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

Ms. Shalini Sharp

Independent Director

2.00

--

Ms. Ramona A. Sequeira

Independent Director

--

Mr. Robert A. (Bob) Essner

Lead Independent Director

--

Ms. Grace M. Puma Whiteford

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

144.48K

+8.57%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

71.89K

+18.29%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

59.92K

+10.11%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

52.85K

+17.96%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

41.33K

+26.65%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Women’s Health

462.00M

28.98%

Cardiovascular

283.00M

17.75%

Non-Opioid Pain, Bone and Dermatology

250.00M

15.68%

Respiratory

220.00M

13.80%

Other

206.00M

12.92%

Biosimilars

173.00M

10.85%

Por regiónUSD

Nombre

Ganancia

Proporción

Europe and Canada

419.00M

26.29%

United States

414.00M

25.97%

Latin America, Middle East, Russia and Africa

285.00M

17.88%

Asia Pacific and Japan

250.00M

15.68%

China

204.00M

12.80%

Other

22.00M

1.38%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Women’s Health

462.00M

28.98%

Cardiovascular

283.00M

17.75%

Non-Opioid Pain, Bone and Dermatology

250.00M

15.68%

Respiratory

220.00M

13.80%

Other

206.00M

12.92%

Biosimilars

173.00M

10.85%

Estadísticas de accionistas

Actualizado: dom., 17 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

13.76%

BlackRock Institutional Trust Company, N.A.

10.88%

State Street Investment Management (US)

3.66%

MFS Investment Management

3.63%

Millennium Management LLC

3.50%

Otro

64.57%

Accionistas

Proporción

The Vanguard Group, Inc.

13.76%

BlackRock Institutional Trust Company, N.A.

10.88%

State Street Investment Management (US)

3.66%

MFS Investment Management

3.63%

Millennium Management LLC

3.50%

Otro

64.57%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

50.05%

Investment Advisor/Hedge Fund

20.42%

Hedge Fund

7.62%

Research Firm

2.69%

Pension Fund

1.84%

Bank and Trust

0.92%

Sovereign Wealth Fund

0.87%

Individual Investor

0.35%

Family Office

0.01%

Otro

15.24%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

1485

219.88M

84.58%

-37.41M

2025Q2

1527

205.34M

78.98%

-50.49M

2025Q1

1611

213.21M

82.04%

-52.34M

2024Q4

1647

218.39M

84.67%

-40.43M

2024Q3

1625

211.80M

82.26%

-47.57M

2024Q2

1676

208.67M

81.14%

-51.47M

2024Q1

1700

205.29M

80.30%

-45.21M

2023Q4

1767

202.90M

79.38%

-24.07M

2023Q3

1835

205.61M

80.45%

-25.35M

2023Q2

2016

205.94M

80.75%

-21.55M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

32.15M

12.37%

+2.54M

+8.57%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

28.28M

10.88%

-627.34K

-2.17%

Jun 30, 2025

State Street Investment Management (US)

9.52M

3.66%

+540.48K

+6.02%

Jun 30, 2025

MFS Investment Management

10.11M

3.89%

-469.39K

-4.44%

Jun 30, 2025

Millennium Management LLC

9.09M

3.5%

+8.11M

+829.74%

Jun 30, 2025

LSV Asset Management

7.99M

3.07%

+8.69K

+0.11%

Jun 30, 2025

UBS Financial Services, Inc.

5.93M

2.28%

+4.25M

+253.22%

Jun 30, 2025

Citadel Advisors LLC

5.46M

2.1%

+1.45M

+36.30%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

4.63M

1.78%

+459.24K

+11.02%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.40M

1.69%

-121.50K

-2.69%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

SPDR S&P Pharmaceuticals ETF

2.5%

Alger Russell Innovation ETF

2.13%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.88%

First Trust Health Care Alphadex Fund

1.87%

Invesco S&P SmallCap Health Care ETF

1.76%

iShares U.S. Pharmaceuticals ETF

1.03%

WisdomTree U.S. SmallCap Dividend Fund

0.79%

Brandes US Small-Mid Cap Value ETF

0.79%

Royce Quant Small-Cap Quality Value ETF

0.78%

Lattice Hartford Multifactor Small Cap ETF

0.73%

SPDR S&P Pharmaceuticals ETF

Proporción2.5%

Alger Russell Innovation ETF

Proporción2.13%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.88%

First Trust Health Care Alphadex Fund

Proporción1.87%

Invesco S&P SmallCap Health Care ETF

Proporción1.76%

iShares U.S. Pharmaceuticals ETF

Proporción1.03%

WisdomTree U.S. SmallCap Dividend Fund

Proporción0.79%

Brandes US Small-Mid Cap Value ETF

Proporción0.79%

Royce Quant Small-Cap Quality Value ETF

Proporción0.78%

Lattice Hartford Multifactor Small Cap ETF

Proporción0.73%

Dividendos



Un total de 1.03B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Feb 13, 2025

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025

Feb 24, 2025

Mar 13, 2025

Feb 24, 2025

Oct 31, 2024

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024

Nov 12, 2024

Dec 12, 2024

Nov 12, 2024

Aug 06, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 12, 2024

Aug 16, 2024

May 02, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024

May 13, 2024

Jun 13, 2024

May 10, 2024

Feb 15, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024

Feb 26, 2024

Mar 14, 2024

Feb 23, 2024

Nov 02, 2023

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023

Nov 13, 2023

Dec 14, 2023

Nov 10, 2023

Aug 08, 2023

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 14, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 14, 2023

Aug 17, 2023

May 04, 2023

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 15, 2023 going ex on May 12, 2023

May 15, 2023

Jun 15, 2023

May 12, 2023

Feb 16, 2023

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 16, 2023 going ex on Feb 24, 2023

Feb 27, 2023

Mar 16, 2023

Feb 24, 2023

Nov 03, 2022

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 15, 2022 going ex on Nov 10, 2022

Nov 14, 2022

Dec 15, 2022

Nov 10, 2022

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos